Pharmacology of Estrogens and Progestins

Introduction/Overview

Estrogens and progestins constitute a fundamental class of steroid hormones with extensive physiological roles and therapeutic applications. These agents are pivotal in regulating the female reproductive system, influencing secondary sexual characteristics, and maintaining bone density, cardiovascular health, and cognitive function. Beyond their endogenous functions, synthetic and natural derivatives are employed therapeutically to manage conditions ranging from contraception and menopausal symptoms to hormone-sensitive cancers and menstrual disorders. The clinical relevance of these hormones is profound, impacting a significant proportion of the population across various life stages. A thorough understanding of their pharmacology is essential for safe and effective prescribing, particularly given the nuanced balance between therapeutic benefits and potential risks, including thromboembolic events and carcinogenic potential.

Learning Objectives

• Classify the major types of estrogens and progestins, distinguishing between endogenous forms, conjugated preparations, and synthetic analogs.
• Explain the molecular mechanism of action for estrogens and progestins, detailing nuclear receptor activation, genomic effects, and rapid non-genomic signaling.
• Compare and contrast the pharmacokinetic profiles of orally administered versus transdermally delivered estrogens and progestins, including key metabolic pathways.
• Evaluate the major therapeutic applications of these hormones, including hormone replacement therapy, contraception, and management of gynecological disorders.
• Identify the spectrum of adverse effects, from common side effects to serious risks like venous thromboembolism and breast cancer, and describe strategies for risk mitigation.

Classification

Estrogens and progestins are classified based on their chemical structure, origin, and pharmacological profile. This classification informs their potency, selectivity, and clinical utility.

Estrogen Classification

Estrogens are categorized into three main groups: natural steroidal estrogens, conjugated estrogens, and synthetic nonsteroidal estrogens.

• Natural Steroidal Estrogens: The primary endogenous estrogen in premenopausal women is 17β-estradiol (E2). Estrone (E1) is a weaker estrogen predominant after menopause, and estriol (E3) is a metabolite produced in high amounts during pregnancy. Pharmaceutical preparations include micronized 17β-estradiol, used for oral and transdermal therapy.
• Conjugated Estrogens: These are mixtures of estrogen sulfates, primarily derived from pregnant mare’s urine (e.g., Premarin® containing estrone sulfate, equilin sulfate) or synthesized (e.g., Cenestin®). They are commonly used in hormone replacement therapy.
• Synthetic Estrogens: This class includes ethinyl estradiol (EE) and mestranol. EE, created by adding an ethinyl group at the C17 position, is resistant to first-pass hepatic metabolism, making it exceptionally potent and the estrogen of choice in most combined oral contraceptives. Nonsteroidal synthetic compounds with estrogenic activity, such as diethylstilbestrol (DES), are now rarely used due to significant toxicity.
• Selective Estrogen Receptor Modulators (SERMs): While not classic estrogens, drugs like tamoxifen, raloxifene, and bazedoxifene are included in discussions of estrogen pharmacology due to their tissue-selective agonist or antagonist actions at estrogen receptors.

Progestin Classification

Progestins are synthetic analogs of the endogenous hormone progesterone. They are grouped by their chemical derivation, which correlates with their pharmacological properties, including androgenic, antiandrogenic, estrogenic, or glucocorticoid-like activity.

• Progesterone and its Derivatives: Natural progesterone (available in micronized oral form, vaginal gels, and injectable solutions) and its retroprogesterone derivative, dydrogesterone, which offers high oral bioavailability and selective progestogenic effects.
• 17α-Hydroxyprogesterone Derivatives: Medroxyprogesterone acetate (MPA) and megestrol acetate. These are potent progestins often used in hormone therapy and oncology. MPA has some glucocorticoid activity.
• 19-Nortestosterone Derivatives: These are structurally related to testosterone and are subdivided into estranes and gonanes.
  • Estranes (First Generation): Norethindrone (norethisterone) and its prodrug, norethindrone acetate. They possess mild androgenic activity.
  • Gonanes (Second/Third Generation): Levonorgestrel, norgestrel, and desogestrel, norgestimate, gestodene. These are more potent and selective for the progesterone receptor. Later generations (e.g., desogestrel) exhibit reduced androgenic activity. Drospirenone, derived from spironolactone, is a newer progestin with antiandrogenic and antimineralocorticoid properties.

Mechanism of Action

The primary mechanism of action for both estrogens and progestins involves binding to and modulating intracellular nuclear receptors, leading to genomic effects. However, rapid, non-genomic signaling pathways also contribute to their physiological and pharmacological actions.

Estrogen Receptor Signaling

Estrogens exert their effects primarily through two nuclear receptor subtypes: estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). These receptors are ligand-activated transcription factors.

• Genomic Signaling Pathway: Upon ligand binding in the cytoplasm, the receptor undergoes a conformational change, dissociates from heat shock proteins, dimerizes (homodimer or ERα/ERβ heterodimer), and translocates to the nucleus. The dimer binds to specific DNA sequences known as estrogen response elements (EREs) in the promoter regions of target genes. Receptor binding recruits coactivator or corepressor complexes, which modulate chromatin structure and the recruitment of RNA polymerase II, thereby regulating gene transcription. The distinct tissue distribution of ERα (predominant in uterus, breast, liver, bone) and ERβ (predominant in ovary, prostate, cardiovascular system, brain) contributes to the tissue-specific effects of estrogens and SERMs.
• Non-Genomic (Rapid) Signaling: Estrogens can also initiate rapid cellular responses (within seconds to minutes) that do not involve gene transcription. These actions are mediated by membrane-associated or cytoplasmic ERs, or potentially through the G protein-coupled estrogen receptor (GPER). Activation of these pathways can lead to rapid stimulation of intracellular second messenger systems, including activation of mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)/Akt, and increased intracellular calcium. These pathways are implicated in the acute vascular effects of estrogen, such as vasodilation.

Progesterone Receptor Signaling

The effects of progesterone and progestins are mediated through two main isoforms of the intracellular progesterone receptor (PR): PR-A and PR-B. PR-B is a stronger transcriptional activator, while PR-A can act as a dominant repressor of PR-B and other steroid receptors.

• Genomic Pathway: Similar to ERs, ligand binding induces receptor dimerization and binding to progesterone response elements (PREs) in DNA, regulating transcription of target genes. Progesterone receptors can also modulate transcription by interacting with other transcription factors, such as STATs and AP-1, in a DNA-binding independent manner (tethering mechanism).
• Non-Genomic Effects: Progesterone can also elicit rapid effects, potentially through membrane-associated PRs or interaction with other receptors. These effects may include modulation of oocyte maturation, neuronal excitability, and sperm acrosome reaction.
• Androgenic, Antiandrogenic, and Other Activities: The biological profile of synthetic progestins is influenced by their binding affinity for other steroid receptors. For example, 19-nortestosterone derivatives may exhibit residual androgenic activity by weakly binding to the androgen receptor, while drospirenone acts as an antagonist at the mineralocorticoid receptor.

Pharmacokinetics

The pharmacokinetic profiles of estrogens and progestins vary widely depending on the specific compound, route of administration, and formulation. These properties directly influence dosing regimens, efficacy, and side effect profiles.

Absorption

Absorption is highly dependent on the route of administration and the lipophilicity of the compound.

• Oral Administration: Natural estradiol (E2) and progesterone are well-absorbed but undergo extensive first-pass hepatic metabolism, leading to low and variable oral bioavailability. Micronization of these hormones increases surface area and improves absorption. Synthetic modifications enhance oral efficacy: ethinyl estradiol is resistant to hepatic breakdown due to its 17α-ethinyl group, and progestins like norethindrone and levonorgestrel are designed for high oral bioavailability.
• Transdermal Administration: Patches, gels, and sprays deliver estradiol directly into the systemic circulation, bypassing first-pass hepatic metabolism. This results in more physiological E2:E1 ratios and avoids the high hepatic exposure associated with oral therapy, which is relevant for the risk of thromboembolism and synthesis of hepatic proteins like sex hormone-binding globulin (SHBG) and angiotensinogen.
• Other Routes: Vaginal rings (for systemic or local delivery), subcutaneous implants, and intramuscular injections (e.g., estradiol valerate, medroxyprogesterone acetate depot) provide sustained release over weeks to years, offering improved adherence but less flexibility in dosing adjustment.

Distribution

Estrogens and progestins are highly lipophilic and distribute widely throughout body tissues. In the plasma, they are extensively bound to plasma proteins.

• Estrogens: Endogenous estradiol is bound approximately 98% to plasma proteins, primarily to sex hormone-binding globulin (SHBG) with high affinity and to albumin with low affinity. Only the free fraction (1-2%) is biologically active. Synthetic ethinyl estradiol increases hepatic synthesis of SHBG.
• Progestins: Binding varies by compound. Progesterone binds to corticosteroid-binding globulin (CBG). Many synthetic progestins bind primarily to albumin, as they have low affinity for SHBG. Their volume of distribution is large, reflecting significant tissue uptake.

Metabolism

Hepatic metabolism is the primary route of biotransformation, involving cytochrome P450 (CYP) enzymes, followed by conjugation (glucuronidation, sulfation).

• Estrogen Metabolism: Estradiol is reversibly oxidized to estrone by 17β-hydroxysteroid dehydrogenase. Both E2 and E1 are then hydroxylated at multiple positions (C-2, C-4, C-16) by CYP enzymes (notably CYP1A2, CYP3A4). 2-Hydroxylation is a major pathway leading to catechol estrogens, which are further methylated by catechol-O-methyltransferase (COMT). 16α-Hydroxylation yields estriol (E3). All metabolites are conjugated for renal excretion. Ethinyl estradiol is metabolized primarily by CYP2C9 and CYP3A4, and its 2-hydroxylation is slower, contributing to its longer half-life. It also undergoes enterolepatic recirculation, which can be interrupted by antibiotics, potentially reducing efficacy.
• Progestin Metabolism: Progesterone is rapidly reduced to inactive pregnanediol metabolites. Synthetic progestins undergo extensive and varied hepatic metabolism, including reduction, hydroxylation, and conjugation. Norethindrone is metabolized to a large number of compounds. Levonorgestrel is less extensively metabolized. Many progestins are metabolized by CYP3A4, making them susceptible to interactions with inducers or inhibitors of this enzyme.

Excretion

Conjugated metabolites of both estrogens and progestins are primarily excreted in the urine. A smaller fraction is eliminated in the bile, with some undergoing enterolepatic recirculation. The elimination half-life varies considerably.

• Estrogens: The half-life of intravenous estradiol is approximately 1 hour, but its metabolic clearance rate is high. Oral conjugated estrogens have a terminal half-life of 10-24 hours due to the sustained release of estrogen sulfates. Ethinyl estradiol has a plasma half-life of 13-27 hours.
• Progestins: The half-life of oral progesterone is very short (≈5 hours). Synthetic progestins have longer half-lives: norethindrone (5-14 hours), levonorgestrel (11-45 hours), and medroxyprogesterone acetate (≈24-48 hours after oral administration, with depot injections providing sustained release over months).

Therapeutic Uses/Clinical Applications

The clinical applications of estrogens and progestins are broad, reflecting their diverse physiological roles. Therapy may involve estrogen alone, progestin alone, or combined regimens.

Hormone Replacement Therapy (HRT) and Menopausal Symptom Management

Estrogen therapy is the most effective treatment for moderate-to-severe vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome of menopause (vaginal atrophy, dyspareunia, urinary symptoms).

• Estrogen-Only Therapy (ET): Prescribed for women who have undergone hysterectomy. For women with an intact uterus, unopposed estrogen dramatically increases the risk of endometrial hyperplasia and carcinoma; therefore, a progestin must be added.
• Combined Estrogen-Progestin Therapy (EPT): The standard for women with a uterus. Progestins are given continuously (daily) or sequentially (e.g., 10-14 days per month) to induce secretory transformation and protect the endometrium.
• Vaginal Estrogen: Low-dose creams, tablets, or rings are used for local treatment of urogenital atrophy with minimal systemic absorption.

Contraception

Combinations of an estrogen (almost always ethinyl estradiol or estradiol valerate) and a progestin are the basis of most hormonal contraceptives.

• Combined Oral Contraceptives (COCs): Inhibit ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). They also thicken cervical mucus and alter the endometrium. Progestin-only pills (mini-pills), implants, and intrauterine systems (e.g., levonorgestrel IUD) work primarily through local progestin effects on cervical mucus and endometrium, with variable suppression of ovulation.
• Long-Acting Reversible Contraceptives (LARCs): Include progestin-only implants (etonogestrel) and intrauterine systems, which provide highly effective contraception for 3-10 years.
• Emergency Contraception: High-dose levonorgestrel or ulipristal acetate (a progesterone receptor modulator) can inhibit or delay ovulation.

Management of Gynecological Disorders

• Dysfunctional Uterine Bleeding and Endometriosis: Combined oral contraceptives, progestin-only therapies (e.g., norethindrone acetate, depot MPA), or levonorgestrel IUDs are used to regulate menstrual cycles, reduce bleeding, and suppress endometrial growth and ectopic implants.
• Polycystic Ovary Syndrome (PCOS): COCs are first-line for managing hyperandrogenism (hirsutism, acne) and regulating menses.
• Premenstrual Dysphoric Disorder (PMDD): COCs containing drospirenone, a progestin with antiandrogenic and antimineralocorticoid activity, are approved for treatment.

Other Therapeutic Uses

• Feminizing Hormone Therapy: Estrogens (often with antiandrogens) are used to induce feminizing characteristics in transgender women.
• Osteoporosis Prevention: Estrogen therapy is effective in preventing postmenopausal bone loss and reducing fracture risk, but it is generally reserved for women at significant fracture risk who cannot tolerate other therapies, due to the risk-benefit profile.
• Hormone-Sensitive Cancers: High-dose progestins (e.g., megestrol acetate) are used in palliative treatment of advanced endometrial and breast cancer. Conversely, estrogen receptor antagonists (e.g., tamoxifen) or aromatase inhibitors are mainstays of breast cancer treatment.
• Support of Pregnancy: Natural progesterone or dydrogesterone is used in assisted reproductive technology (ART) for luteal phase support and in women with a history of recurrent miscarriage due to corpus luteum deficiency.

Adverse Effects

The adverse effect profile of estrogens and progestins is extensive, ranging from common, benign side effects to rare, life-threatening complications. The risk is influenced by dose, route, specific agent, patient age, and comorbidities.

Common Side Effects

• Estrogen-Related: Nausea, breast tenderness, bloating, fluid retention, and headaches. These often diminish with continued use or dose reduction. Withdrawal bleeding or breakthrough bleeding is common with cyclic regimens.
• Progestin-Related: Mood changes (e.g., depression, irritability), acne, weight gain, and fatigue. Androgenic progestins may worsen acne and hirsutism, while those with antiandrogenic properties (e.g., drospirenone) may improve them.

Serious Adverse Reactions

• Venous Thromboembolism (VTE): A well-established risk of estrogen-containing therapies. The relative risk is highest during the first year of use. The risk is greater with oral therapy compared to transdermal, likely due to the first-pass hepatic effect on coagulation factors (increased synthesis of factors VII, VIII, X, and fibrinogen; decreased antithrombin III). The risk also varies by progestin type; some studies suggest a higher risk with third-generation progestins (desogestrel, gestodene) and drospirenone compared to levonorgestrel.
• Cardiovascular Disease: The effect on arterial disease (myocardial infarction, stroke) is complex and age-dependent. In younger, healthy women, the risk is low. In older women (>60 years) or those initiating therapy more than 10 years after menopause, HRT may increase the risk of coronary events and ischemic stroke. This risk appears lower with transdermal estrogens.
• Endometrial Cancer: Unopposed estrogen therapy in women with a uterus increases the risk of endometrial hyperplasia and adenocarcinoma by 5- to 10-fold. Adding adequate progestin for at least 10-14 days per cycle eliminates this excess risk.
• Breast Cancer: Long-term use (typically >5 years) of combined estrogen-progestin therapy is associated with a small but statistically significant increased relative risk of breast cancer (≈1.24). The risk increases with duration of use and appears to decline after discontinuation. The data on estrogen-only therapy in hysterectomized women are less clear, with some studies showing little to no increased risk.
• Gallbladder Disease: Estrogen therapy increases the risk of cholelithiasis and cholecystitis, likely due to increased cholesterol saturation of bile.

Black Box Warnings

Prescribing information for estrogen and estrogen-progestin products contains boxed warnings regarding:

1. Increased risk of endometrial cancer with unopposed estrogen use in women with a uterus.
2. Increased risk of cardiovascular events (myocardial infarction, stroke, venous thromboembolism) and breast cancer with postmenopausal hormone therapy. The warning emphasizes that these products should not be used for the prevention of cardiovascular disease or dementia, and should be prescribed at the lowest effective dose for the shortest duration consistent with treatment goals.
3. For combination oral contraceptives, warnings highlight the increased risk of serious cardiovascular events, particularly in women who smoke and are over 35 years old. Cigarette smoking is an absolute contraindication for COCs in this age group.

Drug Interactions

Significant pharmacokinetic and pharmacodynamic interactions can occur with concomitant use of other medications, potentially altering the efficacy or toxicity of hormonal therapies.

Major Pharmacokinetic Interactions

• Enzyme Inducers: Drugs that induce hepatic CYP enzymes, particularly CYP3A4, can significantly reduce the plasma concentrations of both estrogens and progestins, leading to therapeutic failure (e.g., breakthrough bleeding, contraceptive failure). Potent inducers include rifampin, rifabutin, certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone, and to a lesser extent, topiramate and oxcarbazepine), and the herbal supplement St. John’s wort. Alternative contraception or dose adjustment is required.
• Enzyme Inhibitors: CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, erythromycin, grapefruit juice) may increase plasma levels of hormones, potentially exacerbating side effects like nausea and thromboembolic risk, though clinically significant toxicity is less commonly reported than with induction.
• Antibiotics: Broad-spectrum antibiotics (e.g., ampicillin, tetracyclines) are thought to reduce the enterolepatic recirculation of ethinyl estradiol by altering gut flora, potentially decreasing its plasma concentration. The clinical significance is debated, but backup contraception is often recommended during and for 7 days after antibiotic therapy.

Pharmacodynamic Interactions

• Anticoagulants: Estrogens can reduce the efficacy of anticoagulants like warfarin by increasing clotting factor synthesis, while also increasing the risk of thromboembolism. Careful monitoring of INR is necessary.
• Antihypertensives: Estrogens can cause fluid retention and may antagonize the effects of antihypertensive drugs.
• Antidiabetic Agents: Estrogens may impair glucose tolerance and increase insulin resistance, potentially necessitating adjustment of insulin or oral hypoglycemic doses.
• Other Hormones: Thyroid hormone requirements may increase in hypothyroid patients initiated on estrogen, as estrogens increase thyroxine-binding globulin (TBG) levels.

Contraindications

Absolute contraindications to estrogen-containing therapy generally include:

• Known or suspected pregnancy.
• Undiagnosed abnormal genital bleeding.
• Known or suspected estrogen-dependent neoplasia (e.g., breast cancer, endometrial cancer). Exceptions exist for palliative care.
• Active or history of arterial thromboembolic disease (e.g., MI, stroke) or venous thromboembolism (DVT, PE).
• Active or history of thrombophilic disorders (e.g., factor V Leiden, protein C/S deficiency).
• Severe hepatic dysfunction.
• For combined oral contraceptives: heavy smoking (≥15 cigarettes/day) in women over 35 years of age.

Special Considerations

The use of estrogens and progestins requires careful patient assessment and individualized therapy, particularly in specific populations.

Pregnancy and Lactation

• Pregnancy: Estrogen-progestin combinations are contraindicated and are pregnancy category X. They offer no benefit in supporting pregnancy and may cause fetal harm, including cardiovascular and limb reduction defects (as historically seen with DES). Natural progesterone or dydrogesterone, used for luteal phase support, is considered safe.
• Lactation: Estrogen can suppress milk production and is generally avoided in breastfeeding mothers. Progestin-only contraceptives (mini-pills, implants, depot injections) are considered compatible with breastfeeding, typically initiated 4-6 weeks postpartum.

Pediatric and Adolescent Use

Estrogen-progestin therapy is used in adolescents for contraception, management of dysmenorrhea, heavy menstrual bleeding, and acne. Low-dose COCs are preferred. In cases of delayed puberty, low-dose estrogen may be initiated under specialist guidance to induce pubertal development.

Geriatric Considerations

Initiating systemic hormone therapy in women over age 60 or more than 10 years past menopause is generally not recommended due to an unfavorable risk-benefit ratio for chronic disease prevention. If used for persistent vasomotor symptoms, the lowest effective dose for the shortest duration is advised. Local vaginal estrogen remains a safe and effective long-term option for urogenital symptoms in older women.

Renal and Hepatic Impairment

• Renal Impairment: Dose adjustment is not typically required, but caution is warranted in patients with conditions exacerbated by fluid retention (e.g., hypertension, heart failure). Drospirenone has antimineralocorticoid activity and can increase serum potassium; it is contraindicated in patients with renal insufficiency, adrenal insufficiency, or conditions predisposing to hyperkalemia.
• Hepatic Impairment: Estrogens and progestins are extensively metabolized by the liver. Their use is contraindicated in acute or severe chronic liver disease, including hepatic tumors, cholestatic jaundice, or active viral hepatitis. In mild hepatic impairment, use with caution and monitor liver function. Transdermal therapy, which avoids first-pass metabolism, may be a safer option in select cases of mild impairment, though clinical data are limited.

Summary/Key Points

• Estrogens and progestins are steroid hormones with critical physiological roles, available as natural, conjugated, and synthetic analogs for diverse therapeutic applications.
• Their primary mechanism involves binding to intracellular nuclear receptors (ERα/ERβ, PR-A/PR-B), leading to genomic regulation of target genes, complemented by rapid non-genomic signaling pathways.
• Pharmacokinetics vary significantly: oral administration subjects natural hormones to high first-pass metabolism, while transdermal and parenteral routes provide more direct systemic delivery. Ethinyl estradiol is uniquely potent due to metabolic resistance.
• Major clinical uses include hormone replacement for menopausal symptoms, contraception, and management of gynecological disorders like endometriosis and dysfunctional uterine bleeding.
• The most serious adverse effects are an increased risk of venous thromboembolism (especially with oral estrogens), stroke, myocardial infarction (in older women initiating therapy late), and breast cancer (with long-term combined therapy). Unopposed estrogen causes endometrial hyperplasia and cancer.
• Significant drug interactions occur with hepatic enzyme inducers (e.g., rifampin, anticonvulsants), which can reduce efficacy, and anticoagulants, where estrogens may alter response.
• Therapy must be individualized, with absolute contraindications including pregnancy, undiagnosed vaginal bleeding, history of thromboembolism, and estrogen-dependent cancers. Special caution is required in patients with hepatic impairment.

Clinical Pearls

• For menopausal women with an intact uterus, always combine systemic estrogen with a progestin to prevent endometrial cancer. This is not required for vaginal estrogen used at low doses for local symptoms.
• Transdermal estrogen may offer a safer profile than oral estrogen regarding VTE risk, as it avoids the first-pass hepatic effect on coagulation factors.
• When prescribing combined oral contraceptives, actively screen for smoking status. Women over 35 who smoke should not use COCs due to the high risk of cardiovascular events.
• Consider drug interactions with enzyme-inducing medications a major cause of contraceptive failure or breakthrough bleeding in hormone therapy. Alternative non-hormonal contraception or higher-dose hormonal regimens may be necessary.
• The decision to use postmenopausal hormone therapy should be based on a personalized assessment of the patient’s symptom burden, age, time since menopause, and individual risk factors for VTE, cardiovascular disease, and breast cancer, with treatment duration re-evaluated annually.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.